Loading company…
Singmed develops inhalers and other drug delivery devices for pulmonary, nasal and related treatments.
Singmed designs and manufactures drug delivery devices, including single- and multi-dose dry powder inhalers, soft mist inhalers and nasal sprays. Its products are used to deliver treatments for asthma, COPD, nasal and brain diseases. Founded in 2016 by Albert Zhao, the company is based in Suzhou, China. In April 2026, it raised approximately CNY 300 million in Series B funding led by Oriza Holdings, with participation from Creacion Ventures, UOB Venture Management, Jolmo Capital, Changshu Jingkai Holdings, Changshu Guofa Venture Capital, and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in